Raymond James & Associates Alkermes Plc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Alkermes Plc. stock. As of the latest transaction made, Raymond James & Associates holds 18,224 shares of ALKS stock, worth $529,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,224
Previous 19,097 4.57%
Holding current value
$529,224
Previous $460,000 10.87%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
SELL
$23.01 - $28.55 $20,087 - $24,924
-873 Reduced 4.57%
18,224 $510,000
Q2 2024

Jul 19, 2024
BUY
$23.21 - $27.24 $16,479 - $19,340
710 Added 3.86%
19,097 $460,000
Q1 2024

Apr 22, 2024
BUY
$26.4 - $32.56 $12,408 - $15,303
470 Added 2.62%
18,387 $497,000
Q4 2023

Jan 16, 2024
SELL
$23.37 - $28.68 $202,734 - $248,799
-8,675 Reduced 32.62%
17,917 $497,000
Q3 2023

Oct 24, 2023
BUY
$27.17 - $31.97 $176,876 - $208,124
6,510 Added 32.42%
26,592 $744,000
Q2 2023

Jul 25, 2023
BUY
$28.34 - $33.63 $15,700 - $18,631
554 Added 2.84%
20,082 $628,000
Q1 2023

Apr 14, 2023
SELL
$25.31 - $29.02 $8,959 - $10,273
-354 Reduced 1.78%
19,528 $550,000
Q4 2022

Feb 08, 2023
SELL
$21.94 - $26.24 $107,154 - $128,156
-4,884 Reduced 19.72%
19,882 $519,000
Q3 2022

Oct 25, 2022
SELL
$22.0 - $31.87 $48,840 - $70,751
-2,220 Reduced 8.23%
24,766 $553,000
Q2 2022

Aug 12, 2022
SELL
$26.4 - $30.54 $152,512 - $176,429
-5,777 Reduced 17.63%
26,986 $804,000
Q1 2022

May 11, 2022
BUY
$23.07 - $27.99 $430,647 - $522,489
18,667 Added 132.43%
32,763 $862,000
Q4 2021

Feb 08, 2022
SELL
$21.47 - $32.08 $35,081 - $52,418
-1,634 Reduced 10.39%
14,096 $328,000
Q3 2021

Nov 02, 2021
BUY
$23.37 - $32.13 $162,608 - $223,560
6,958 Added 79.32%
15,730 $485,000
Q2 2021

Aug 11, 2021
BUY
$18.78 - $25.15 $164,738 - $220,615
8,772 New
8,772 $215,000
Q4 2018

Feb 11, 2019
SELL
$27.94 - $44.61 $699,366 - $1.12 Million
-25,031 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$38.6 - $46.12 $12,120 - $14,481
314 Added 1.27%
25,031 $1.06 Million
Q2 2018

Aug 14, 2018
SELL
$40.56 - $51.36 $431,639 - $546,573
-10,642 Reduced 30.1%
24,717 $1.02 Million
Q1 2018

May 14, 2018
BUY
$53.61 - $67.26 $552,343 - $692,979
10,303 Added 41.12%
35,359 $2.05 Million
Q4 2017

Feb 14, 2018
SELL
$47.69 - $55.39 $3,576 - $4,154
-75 Reduced 0.3%
25,056 $1.37 Million
Q3 2017

Nov 13, 2017
BUY
$49.16 - $54.45 $34,903 - $38,659
710 Added 2.91%
25,131 $1.28 Million
Q2 2017

Aug 14, 2017
BUY
N/A
24,421
24,421 $1.42 Million

Others Institutions Holding ALKS

# of Institutions
403
Shares Held
176M
Call Options Held
901K
Put Options Held
400K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.77B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email